Dashboard
Manage Tickers

ALKSAlkermes plc.

Nasdaq alkermes.com


$ 23.86 $ -0.15 (-0.62 %)    

Thursday, 02-May-2024 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 23.86
$ 23.92
$ 0.00 x 0
$ 0.00 x 0
$ 23.40 - $ 23.96
$ 20.46 - $ 32.88
1,987,877
na
4.13B
$ 0.58
$ 9.40
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 10-25-2023 09-30-2023 10-Q
4 07-26-2023 06-30-2023 10-Q
5 04-26-2023 03-31-2023 10-Q
6 02-16-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 07-27-2022 06-30-2022 10-Q
9 04-27-2022 03-31-2022 10-Q
10 02-16-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-11-2021 12-31-2020 10-K
15 10-29-2020 09-30-2020 10-Q
16 07-29-2020 06-30-2020 10-Q
17 04-29-2020 03-31-2020 10-Q
18 02-13-2020 12-31-2019 10-K
19 10-23-2019 09-30-2019 10-Q
20 07-25-2019 06-30-2019 10-Q
21 04-25-2019 03-31-2019 10-Q
22 02-15-2019 12-31-2018 10-K
23 10-23-2018 09-30-2018 10-Q
24 07-26-2018 06-30-2018 10-Q
25 04-26-2018 03-31-2018 10-Q
26 02-16-2018 12-31-2017 10-K
27 10-26-2017 09-30-2017 10-Q
28 07-27-2017 06-30-2017 10-Q
29 04-27-2017 03-31-2017 10-Q
30 02-17-2017 12-31-2016 10-K
31 11-02-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-28-2016 03-31-2016 10-Q
34 02-25-2016 12-31-2015 10-K
35 10-29-2015 09-30-2015 10-Q
36 07-30-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 02-24-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-31-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

7-analysts-assess-alkermes-what-you-need-to-know
7 Analysts Assess Alkermes: What You Need ...
05/02/2024 18:00:24

hc-wainwright--co-reiterates-neutral-on-alkermes-maintains-35-price-target
HC Wainwright & Co. Reiterates Neutral on ...
05/02/2024 17:29:57

HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $35 price target.

Core News & Articles
Alkermes Has Completed The Previously Anno...
05/02/2024 12:04:50

alkermes-q1-2024-adj-eps-from-continuing-operations-044-misses-058-estimate
Alkermes Q1 2024 Adj EPS From Continuing O...
05/01/2024 11:18:49

Alkermes (NASDAQ:ALKS) reported quarterly Adj EPS From Continuing Operations of $0.44 per share which missed the analyst consen...

alkermes-reiterates-its-financial-expectations-for-2024
Alkermes Reiterates Its Financial Expectat...
05/01/2024 11:10:44

alkermes-q1-sales-350372m-miss-360258m-estimate
Alkermes Q1 Sales $350.372M Miss $360.258M...
05/01/2024 11:03:51

Alkermes (NASDAQ:ALKS) reported quarterly sales of $350.372 million which missed the analyst consensus estimate of $360.258 mil...

alkermes-expects-to-initiate-vibrance-2-phase-2-study-in-narcolepsy-type-2-in-2h-2024
Alkermes Expects To Initiate Vibrance-2 Ph...
04/24/2024 11:05:09

alkermes-initiates-vibrance-1-phase-2-study-of-alks-2680-for-narcolepsy-type-1
Alkermes Initiates Vibrance-1 Phase 2 Stud...
04/24/2024 11:04:49

hc-wainwright--co-reiterates-neutral-on-alkermes-maintains-35-price-target
HC Wainwright & Co. Reiterates Neutral on ...
04/19/2024 10:17:15

HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $35 price target.

alkermes-sleeping-disorder-studies-data-look-excellent-analyst-says
Alkermes' Sleeping Disorder Studies' Data ...
04/09/2024 18:23:46

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in ...

breaking-down-alkermes-5-analysts-share-their-views
Breaking Down Alkermes: 5 Analysts Share T...
04/09/2024 17:01:01

jefferies-maintains-buy-on-alkermes-raises-price-target-to-50
Jefferies Maintains Buy on Alkermes, Raise...
04/09/2024 16:07:41

Jefferies analyst Akash Tewari maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target from $42 to $50.

alkermes-announces-positive-topline-results-from-phase-1b-study-of-alks-2680-in-patients-with-narcolepsy-type-2-and-idiopathic-hypersomnia
Alkermes Announces Positive Topline Result...
04/09/2024 11:03:45

alkermes-shares-long-term-lybalvi-treatment-data-for-schizophrenia-at-sirs-2024-congress
Alkermes Shares Long-Term LYBALVI Treatmen...
04/08/2024 11:09:59

 Alkermes plc (NASDAQ:ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia In...

piper-sandler-reiterates-overweight-on-alkermes-maintains-39-price-target
Piper Sandler Reiterates Overweight on Alk...
04/01/2024 14:28:28

Piper Sandler analyst David Amsellem reiterates Alkermes (NASDAQ:ALKS) with a Overweight and maintains $39 price target.

the-analyst-verdict-alkermes-in-the-eyes-of-4-experts
The Analyst Verdict: Alkermes In The Eyes ...
03/19/2024 13:01:10

baird-initiates-coverage-on-alkermes-with-outperform-rating-announces-price-target-of-37
Baird Initiates Coverage On Alkermes with ...
03/19/2024 08:52:03

Baird analyst Joel Beatty initiates coverage on Alkermes (NASDAQ:ALKS) with a Outperform rating and announces Price Target o...

a-look-into-healthcare-sector-value-stocks
A Look Into Healthcare Sector Value Stocks
03/11/2024 14:43:58

alkermes-expects-fiscal-year-2024-revenues-of-15b-16b-versus-consensus-of-152b-and-expects-to-generate-30-ebitda-margin-in-2024
Alkermes Expects Fiscal Year 2024 Revenues...
02/15/2024 12:19:38

alkermes-board-of-directors-approved-a-new-share-repurchase-program-authorizing-the-company-to-repurchase-up-to-400m
Alkermes' Board Of Directors Approved A Ne...
02/15/2024 12:17:15

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION